Loading
AT
Astria Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 05 Feb 2024.
Astria Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Astria Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Between 18 October 2025 and 18 October 2026, 3 insiders published 3 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 3 filings, this issuer sits below that mark. Looking back to 2021, when coverage begins, insiders filed 5 purchases and 2 sales.
There has been no open-market purchase by an insider of Astria Therapeutics, Inc. for at least a year.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
14
Thresholds
n/a
Buy Volume
€45M
5 ops. · all time
Sell Volume
€102,699
2 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
Net income-US$81.2M
Last declaration on 23 January 2026
Declarations14 total
263,321 sharesCommon StockSEC:0000905148-26-000324:0
4,377 sharesCommon StockSEC:0000905148-26-000322:0
10 sharesCommon StockSEC:0000905148-26-000319:0
10,000 shares@ US$3.8720.7% of flowCommon StockSEC:0001104659-24-043092:0
2,481,350 shares@ US$12.0961.4% of flowCommon StockSEC:0001062993-24-001979:0
Canonical exit: 1 May 2024 (T+90)
800 shares@ US$3.871.6% of flowCommon StockSEC:0001104659-24-008327:0
800 shares@ US$11.0154.7% of flowCommon StockSEC:0001104659-24-008327:1
9,200 shares@ US$3.8718.8% of flowCommon StockSEC:0001104659-24-008327:2
9,200 shares@ US$11.14754.2% of flowCommon StockSEC:0001104659-24-008327:3
740,000 shares@ US$6.209.3% of flowCommon StockSEC:0001062993-23-023077:0
Canonical exit: 20 Mar 2024 (T+90)
614,062 shares@ US$6.5148.4% of flowCommon StockSEC:0001062993-23-019533:0
Canonical exit: 14 Jan 2024 (T+90)
908,265 shares@ US$11.0120.9% of flowCommon StockSEC:0001062993-22-024291:0
Canonical exit: 19 Mar 2023 (T+90)
100 shares@ US$6.695100.0% of flowCommon StockSEC:0001104659-21-143035:0
Canonical exit: 17 Feb 2022 (T+90)
263,321 shares0Common StockSEC:0001104659-21-118359:0
14 of 14 declarations
About Astria Therapeutics, Inc.
Astria Therapeutics, Inc. is a U.S.-listed biopharmaceutical company traded on the NASDAQ in the United States (United States), focused on allergic and immunologic diseases. For French-speaking investors evaluating the name, Astria should be viewed primarily as a clinical-stage biotech, with valuation driven more by pipeline execution, regulatory milestones, and strategic transactions than by recurring commercial revenues.
The company was incorporated in Delaware on June 26, 2008. Its operational base has been associated with Boston, Massachusetts, placing it in one of the most important U.S. biotech hubs. Over time, Astria has built a portfolio centered on hereditary angioedema (HAE), a rare and chronic condition, and has used that program as the anchor for its broader immunology strategy.
Read moreShow less
Astria’s lead asset is navenibart, a long-acting monoclonal antibody inhibitor of plasma kallikrein designed for the preventive treatment of HAE. Recent company disclosures highlighted positive clinical data across its ALPHA-STAR and ALPHA-SOLAR development program, alongside the launch of Phase 3 studies such as ALPHA-ORBIT and ORBIT-EXPANSE. The investment case has increasingly centered on navenibart’s potential differentiation, especially around efficacy, safety, and a less frequent dosing profile that could support patient convenience and commercial adoption.
The company has also pursued geographic expansion through a licensing agreement with Kaken Pharmaceutical for the development and commercialization of navenibart in Japan. This is noteworthy because it indicates Astria is not only advancing a lead asset clinically, but also selectively building regional partnerships that may help monetize the program beyond the core U.S. market.
In parallel, Astria is advancing STAR-0310, an OX40 antagonist being developed for atopic dermatitis. This second program broadens the pipeline beyond HAE and shows management’s intent to create optionality in immunology. That said, Astria remains highly dependent on successful clinical execution in a competitive field where larger pharmaceutical groups and specialty biotechs are also targeting HAE and related immune-mediated diseases.
Recent corporate developments are especially important. Astria reported positive clinical updates on navenibart, initiated Phase 3 work, and secured the Japan license deal. Most significantly, BioCryst Pharmaceuticals announced an acquisition of Astria, and Astria stockholders approved the transaction in January 2026. For investors, that means Astria is best understood as a NASDAQ-listed U.S. biotech whose near-term narrative has been shaped by clinical progress and a major M&A process, rather than by a mature commercial product base.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
